Close menu

June 20th, 2022 | 10:57 CEST

A lot of movement at Rheinmetall, Aspermont and Deutsche Telekom

  • Investments
  • Defense
  • Fintech
Photo credits:

Stock markets around the globe continue to be in a downward spiral. Fears of a recession on the one hand and concerns about possible major interest rate hikes on the other have sent stock markets tumbling to new interim lows. In the process, the US markets, driven by technology stocks, entered a technical bear market last week with a loss of more than 20%. Nevertheless, most individual stocks are still clearly up since the lows in the wake of the Corona pandemic. Thus, in the current market environment, there are once again favourable entry opportunities in selected stocks.

time to read: 3 minutes | Author: Stefan Feulner

Table of contents:

    New test of the all-time high

    Far below the current price level of EUR 211.30, the shares of Germany's largest defence group Rheinmetall were trading at around EUR 80 when the Corona pandemic broke out in March 2020. Companies that produced tanks, weapons systems or ammunition were not needed to fight the virus and were still considered "socially harmful" until mid-February this year. But this state of affairs changed abruptly after Russia invaded Ukraine. Not only in Germany but to ensure peace in the world, there were discussions about significant increases in the respective defense expenditures, which would ensure a saturated growth for the respective corporations, such as Rheinmetall.

    The announcement of a special fund of EUR 100 billion for the German Armed Forces gave the Rheinmetall share such a boost that its price has since exploded from around EUR 92 to EUR 225. Irrespective of the raw material bottlenecks, which could lead to delays and low margins, and the already extremely ambitious valuation, the Düsseldorf stock is moving back towards its all-time high after a price setback. However, when it reaches it, the momentum for a new breakout will likely be lacking due to the continued strong overbought condition. Already invested investors should secure their investment with a tight stop.

    Aspermont - New platform creates fantasy

    In contrast, the business of the world's largest B2B service provider for the mining industry, Aspermont, could gain momentum. The digital media company, which operates around 30 brands in the mining, energy and agricultural sectors in its portfolio and provides over 3.6 million users in 190 countries with high-quality content, is about to reach its next milestone by entering the fintech sector. Especially with booming commodity markets and demand for financing in the mining sector, the time to launch the "Blue Horseshoe" platform is prime.

    With the establishment of a fintech joint venture with the two partners, Spark Plus and International Pacific Capital, the first step is to launch the platform to raise capital for professional investors on the ASX market. In the process, Aspermont owns the largest share in the newly founded company with a 44% stake. Spark Plus is a management consulting firm specializing in roadshows for Asian companies, while securities trader IPC provides asset management and corporate advisory services to large investors in Asia and Australia.

    From a strategic perspective, the mining sector platform will likely be used as a proof-of-concept to expand this to other segments and countries. Fundamentally, Aspermont is well equipped. In addition to a cash cushion of EUR 4.4 million with a strongly growing operating cash flow and a gross margin of currently 65%, further growth is guaranteed. The reintroduction of live events after the corona-related closures also has a positive effect on the figures.

    The stock market value of Aspermont amounts to EUR 30.94 million at a share price of EUR 0.013. The analysts of GBC AG see a target price of EUR 0.07, which would mean a more than fivefold increase compared to the current share price at EUR 0.013.

    Signs of strength at Telekom

    In contrast to the overall market, the Deutsche Telekom share has shown a strong recovery since Russia invaded Ukraine. After highs of EUR 17.81 before the war in Europe, the share lost almost 20% of its value at the beginning of March. However, this was followed by a strong rebound that took the telecoms company's stock to a new high for the year at EUR 19.30. The market capitalization currently amounts to EUR 89.97 billion.

    The Bloomberg news agency has now reported that there are several interested parties for the EUR 20 billion radio tower division of the Bonn-based company. A consortium of financial investors, KKR, Global Infrastructure Partners and Stonepeak Partners, is said to have submitted a binding offer for a controlling interest in the business, Bloomberg reported, citing people familiar with the matter. This means competition for the consortium of investment firms Brookfield Asset Management and Cellnex Telecom from Spain. Vantage Towers, the radio mast division that Vodafone took public is said to be a third interested party. However, no confirmation of the alleged bidding companies has yet been given.

    The correction on the stock markets continues due to recession fears and concerns about rising inflation. Rheinmetall is the clear outperformer but already ambitiously valued. Deutsche Telekom is also outperforming the market. Aspermont offers enormous potential at current levels.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author

    Related comments:

    Commented by Juliane Zielonka on December 1st, 2022 | 10:44 CET

    Aspermont, Twitter, Apple - Strong numbers, strong visions and marketplace power

    • Digitization
    • Commodities
    • Investments

    The Australian media company for the commodities industry has presented its latest figures. The results are impressive, with total revenue up 17% YOY, among other things. This industry pioneer illustrates just how valuable access to high-quality information can be. Perhaps soon to disappear from the scene is Elon Musk's Twitter: Find out how strong its dependence on the App Store giant is and what impact Apple fees may have on its revenue model here.


    Commented by Stefan Feulner on December 1st, 2022 | 09:46 CET

    BYD, Auxico Resources, Hensoldt, Rheinmetall - Prepared for the future

    • Mining
    • Gold
    • RareEarths
    • Defense

    Russia's invasion of Ukraine at the end of February this year changed everything. While global stock markets fell into a state of shock, shares in defense companies boomed. With the arms buildup in the Western world, the future looks bright for companies that were still viewed critically before the war of aggression. However, in order to produce enough tanks, aircraft and other war equipment, the industry needs a variety of critical metals for which demand already exceeds supply.


    Commented by Fabian Lorenz on November 30th, 2022 | 13:31 CET

    Biotech stocks in focus: Morphosys, Evotec, Bayer, BioNxt Solutions

    • Biotechnology
    • Cancer
    • Investments

    Biotech stocks have struggled in 2022. In Germany, BioNTech has overtaken the previous heavyweights Morphosys and Evotec in record time. Morphosys shocked investors with data on its Alzheimer's hope. Analysts lowered their thumbs, and short-sellers discovered the stock for themselves. Evotec has been quiet this year. Analysts think the valuation is attractive, but meeting earnings guidance in the current year is not a given. BioNxt shares have jumped recently, and if the positive newsflow continues into 2023, a re-rating is possible. At Bayer, the pharmaceuticals division is also developing positively. Conclusion: investors should position themselves for the biotech year 2023.